Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) COO Matthew E. Korenberg sold 6,275 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $104.10, for a total value of $653,227.50. Following the transaction, the chief operating officer now owns 50,777 shares of the company’s stock, valued at $5,285,885.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Ligand Pharmaceuticals Trading Up 0.6 %
NASDAQ LGND opened at $99.38 on Friday. The firm has a market capitalization of $1.79 billion, a P/E ratio of 19.22 and a beta of 1.01. The firm’s fifty day moving average price is $102.93 and its two-hundred day moving average price is $88.13. Ligand Pharmaceuticals Incorporated has a 1 year low of $49.24 and a 1 year high of $112.13.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.34. Ligand Pharmaceuticals had a net margin of 29.69% and a return on equity of 7.91%. The company had revenue of $41.50 million for the quarter, compared to analysts’ expectations of $33.04 million. During the same period in the prior year, the firm earned $1.10 EPS. Ligand Pharmaceuticals’s quarterly revenue was up 57.2% compared to the same quarter last year. On average, research analysts anticipate that Ligand Pharmaceuticals Incorporated will post 3.54 EPS for the current fiscal year.
Institutional Trading of Ligand Pharmaceuticals
Analysts Set New Price Targets
A number of equities analysts have weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $130.00 price target on shares of Ligand Pharmaceuticals in a research report on Wednesday, August 7th. Benchmark raised their target price on shares of Ligand Pharmaceuticals from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Craig Hallum lifted their price target on shares of Ligand Pharmaceuticals from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, July 9th. Finally, HC Wainwright restated a “buy” rating and set a $144.00 price objective on shares of Ligand Pharmaceuticals in a research note on Thursday, August 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Ligand Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $131.00.
Read Our Latest Report on Ligand Pharmaceuticals
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
See Also
- Five stocks we like better than Ligand Pharmaceuticals
- How to Invest in the Best Canadian Stocks
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Bank Stocks – Best Bank Stocks to Invest In
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.